|Brand name(s), other common name(s)||Venclexta®|
|Drug type||BCL-2 inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Venetoclax is FDA approved for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.
Side effects needing medical attention
Neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were pneumonia, febrile neutropenia, pyrexia (fever), autoimmune hemolytic anemia, anemia, and tumor lysis syndrome (TLS).